The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

The Top 5 Biosimilar Articles for the Week of March 10

March 14th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 10, 2025.

More Ustekinumab Biosimilars Join US Market Share Fight

March 13th 2025

By Skylar Jeremias

Article

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 others that launched earlier this year.

Updates on the Use of Biosimilars for Pediatric Patients With Rheumatic Disease

March 12th 2025

By Sabina Alikhanov Palmieri, PharmD

Article

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab Competitors

March 11th 2025

By Ha Kung Wong, JD

Article

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation continues to shape the competitive landscape.

BioRationality: FDA Needs More Time Before Working With USP on Biosimilars Development

March 10th 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz Niazi, PhD, urges the FDA to let the USPharmacopeia (USP) create product release specifications for biosimilars to cut costs, speed development, and enhance accessibility.

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

March 9th 2025

By Skylar Jeremias

Podcast

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

FDA Approves First Omalizumab Biosimilar

March 7th 2025

By Skylar Jeremias

Article

Celltrion's Omlyclo (omalizumab-igec) is the first omalizumab biosimilar to be approved for US patients, and it was approved with interchangeability, making it easier for patients to switch to the Xolair competitor.

The Top 5 Biosimilar Articles for the Week of March 3

March 7th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 3, 2025.

From Amjevita to Zarxio: A Decade of US Biosimilar Approvals

March 6th 2025

By Skylar Jeremias

Article

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.

Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient Care

March 5th 2025

By Kennedy Ferruggia

Article

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.